Insulet Corporation (NASDAQ:PODD) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings estimates for shares of Insulet Corporation in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy expects that the medical instruments supplier will earn ($0.09) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $48.00 target price on the stock. Jefferies Group also issued estimates for Insulet Corporation’s Q2 2018 earnings at ($0.06) EPS and FY2018 earnings at $0.13 EPS.
Several other equities analysts have also recently commented on the stock. ValuEngine raised shares of Insulet Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $47.00 price target on shares of Insulet Corporation in a research report on Monday, May 22nd. Canaccord Genuity reaffirmed a “hold” rating and set a $50.00 price target (up previously from $42.00) on shares of Insulet Corporation in a research report on Tuesday, July 11th. BidaskClub raised shares of Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $52.00 price target on shares of Insulet Corporation in a research report on Friday, July 14th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $49.69.
ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/08/08/jefferies-group-comments-on-insulet-corporations-q1-2018-earnings-nasdaqpodd.html.
Insulet Corporation (NASDAQ PODD) traded up 0.74% on Monday, reaching $54.28. The company had a trading volume of 34,888 shares. Insulet Corporation has a 12 month low of $30.69 and a 12 month high of $54.43. The firm has a 50-day moving average of $50.00 and a 200-day moving average of $44.62. The stock’s market capitalization is $3.14 billion.
Insulet Corporation (NASDAQ:PODD) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.88% and a negative net margin of 7.30%. The firm had revenue of $110 million during the quarter, compared to analysts’ expectations of $106.23 million. During the same period in the previous year, the firm posted ($0.08) EPS. Insulet Corporation’s revenue for the quarter was up 26.0% on a year-over-year basis.
A number of institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its position in shares of Insulet Corporation by 2.0% in the first quarter. UBS Asset Management Americas Inc. now owns 192,168 shares of the medical instruments supplier’s stock worth $8,281,000 after buying an additional 3,775 shares in the last quarter. Swiss National Bank boosted its position in shares of Insulet Corporation by 1.9% in the first quarter. Swiss National Bank now owns 94,300 shares of the medical instruments supplier’s stock worth $4,063,000 after buying an additional 1,800 shares in the last quarter. Geneva Advisors LLC boosted its position in shares of Insulet Corporation by 4.3% in the first quarter. Geneva Advisors LLC now owns 21,711 shares of the medical instruments supplier’s stock worth $936,000 after buying an additional 886 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Insulet Corporation by 28.6% in the first quarter. Tocqueville Asset Management L.P. now owns 45,000 shares of the medical instruments supplier’s stock worth $1,939,000 after buying an additional 10,000 shares in the last quarter. Finally, Rockefeller Financial Services Inc. boosted its position in shares of Insulet Corporation by 2.1% in the first quarter. Rockefeller Financial Services Inc. now owns 369,860 shares of the medical instruments supplier’s stock worth $15,937,000 after buying an additional 7,692 shares in the last quarter.
In other Insulet Corporation news, SVP Michael P. Spears bought 2,500 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were purchased at an average price of $40.59 per share, with a total value of $101,475.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jessica Hopfield bought 2,580 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was acquired at an average cost of $38.68 per share, for a total transaction of $99,794.40. The disclosure for this purchase can be found here. Insiders acquired 8,080 shares of company stock worth $317,339 in the last three months. 2.60% of the stock is currently owned by corporate insiders.
Insulet Corporation Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.